Savvy Advisors Inc. Acquires 1,875 Shares of Eli Lilly and Company (NYSE:LLY)

Savvy Advisors Inc. lifted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 99.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,767 shares of the company's stock after acquiring an additional 1,875 shares during the period. Savvy Advisors Inc.'s holdings in Eli Lilly and Company were worth $2,908,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Stamos Capital Partners L.P. raised its position in Eli Lilly and Company by 70.2% in the 4th quarter. Stamos Capital Partners L.P. now owns 1,940 shares of the company's stock valued at $1,498,000 after buying an additional 800 shares during the last quarter. Bragg Financial Advisors Inc grew its stake in shares of Eli Lilly and Company by 3.4% during the 4th quarter. Bragg Financial Advisors Inc now owns 12,013 shares of the company's stock worth $9,274,000 after acquiring an additional 397 shares in the last quarter. BTG Pactual Asset Management US LLC grew its stake in shares of Eli Lilly and Company by 18.8% during the 4th quarter. BTG Pactual Asset Management US LLC now owns 2,127 shares of the company's stock worth $1,692,000 after acquiring an additional 336 shares in the last quarter. Granite Investment Partners LLC raised its holdings in shares of Eli Lilly and Company by 11.6% in the fourth quarter. Granite Investment Partners LLC now owns 41,806 shares of the company's stock valued at $32,274,000 after purchasing an additional 4,335 shares during the last quarter. Finally, WealthTrust Axiom LLC lifted its position in shares of Eli Lilly and Company by 1.4% in the fourth quarter. WealthTrust Axiom LLC now owns 10,544 shares of the company's stock worth $8,140,000 after purchasing an additional 143 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a research note on Friday, January 17th. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price objective for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Guggenheim decreased their target price on shares of Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating for the company in a research note on Monday. Finally, Citigroup dropped their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. Two equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $1,012.00.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded up $2.20 during trading on Tuesday, reaching $756.55. 2,439,271 shares of the company's stock traded hands, compared to its average volume of 3,387,076. The firm's 50-day moving average is $832.96 and its 200 day moving average is $821.54. The company has a market capitalization of $717.34 billion, a P/E ratio of 64.61, a PEG ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.